Lotus Pharmaceutical Co Ltd (1795) - Total Assets

Latest as of December 2025: NT$106.15 Billion TWD ≈ $3.34 Billion USD

Based on the latest financial reports, Lotus Pharmaceutical Co Ltd (1795) holds total assets worth NT$106.15 Billion TWD (≈ $3.34 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 1795 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Lotus Pharmaceutical Co Ltd - Total Assets Trend (2009–2025)

This chart illustrates how Lotus Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore Lotus Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

Lotus Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Lotus Pharmaceutical Co Ltd's total assets of NT$106.15 Billion consist of 24.9% current assets and 75.1% non-current assets.

Asset Category	Amount (TWD)	% of Total Assets
Cash & Equivalents	NT$0.00	7.3%
Accounts Receivable	NT$7.80 Billion	7.4%
Inventory	NT$9.65 Billion	9.1%
Property, Plant & Equipment	NT$0.00	0.0%
Intangible Assets	NT$25.32 Billion	23.9%
Goodwill	NT$31.95 Billion	30.1%

Asset Composition Trend (2009–2025)

This chart illustrates how Lotus Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Lotus Pharmaceutical Co Ltd market cap and net worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Lotus Pharmaceutical Co Ltd's current assets represent 24.9% of total assets in 2025, a decrease from 54.4% in 2009.
Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 15.6% in 2009.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 0.0% in 2009.
Asset Diversification: The largest asset category is goodwill at 30.1% of total assets.

Lotus Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Lotus Pharmaceutical Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Sweden	Skr81.26 Billion
Aurobindo Pharma Limited NSE:AUROPHARMA	India	Rs585.02 Billion
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	China	CN¥14.18 Billion
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	China	CN¥19.57 Billion
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	China	CN¥10.37 Billion
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	China	CN¥7.28 Billion
Xeris Pharmaceuticals Inc NASDAQ:XERS	USA	$392.01 Million
Procter & Gamble Health Limited NSE:PGHL	India	Rs8.94 Billion

Lotus Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.57	2.14	1.93
Quick Ratio	1.00	1.69	1.39
Cash Ratio	0.00	0.00	0.00
Working Capital	NT$9.57 Billion	NT$9.66 Billion	NT$3.74 Billion

Lotus Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Lotus Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	2.61
Latest Market Cap to Assets Ratio	0.01
Asset Growth Rate (YoY)	164.7%
Total Assets	NT$106.15 Billion
Market Capitalization	$1.58 Billion USD

Valuation Analysis

Below Book Valuation: The market values Lotus Pharmaceutical Co Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Lotus Pharmaceutical Co Ltd's assets grew by 164.7% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Lotus Pharmaceutical Co Ltd (2009–2025)

The table below shows the annual total assets of Lotus Pharmaceutical Co Ltd from 2009 to 2025.

Year	Total Assets	Change
2025-12-31	NT$106.15 Billion ≈ $3.34 Billion	+164.72%
2024-12-31	NT$40.10 Billion ≈ $1.26 Billion	+21.55%
2023-12-31	NT$32.99 Billion ≈ $1.04 Billion	+11.74%
2022-12-31	NT$29.53 Billion ≈ $930.23 Million	+39.13%
2021-12-31	NT$21.22 Billion ≈ $668.61 Million	+7.43%
2020-12-31	NT$19.75 Billion ≈ $622.34 Million	+10.24%
2019-12-31	NT$17.92 Billion ≈ $564.51 Million	+20.63%
2018-12-31	NT$14.85 Billion ≈ $467.97 Million	-5.14%
2017-12-31	NT$15.66 Billion ≈ $493.35 Million	+2.72%
2016-12-31	NT$15.24 Billion ≈ $480.27 Million	-1.66%
2015-12-31	NT$15.50 Billion ≈ $488.40 Million	-4.72%
2014-12-31	NT$16.27 Billion ≈ $512.60 Million	+713.28%
2013-12-31	NT$2.00 Billion ≈ $63.03 Million	+84.37%
2012-12-31	NT$1.09 Billion ≈ $34.19 Million	-3.19%
2011-12-31	NT$1.12 Billion ≈ $35.31 Million	-1.75%
2010-12-31	NT$1.14 Billion ≈ $35.94 Million	+61.36%
2009-12-31	NT$706.92 Million ≈ $22.27 Million	--

About Lotus Pharmaceutical Co Ltd

TW:1795 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$1.58 Billion

NT$50.20 Billion TWD

Market Cap Rank

#7165 Global

#223 in Taiwan

Share Price

NT$191.00

Change (1 day)

-2.30%

52-Week Range

NT$186.00 - NT$363.00

All Time High

NT$363.00